Dolby Laboratories (NYSE:DLB) Given “Buy” Rating at Rosenblatt Securities

Dolby Laboratories (NYSE:DLB)‘s stock had its “buy” rating reaffirmed by analysts at Rosenblatt Securities in a research note issued on Thursday,Benzinga reports. They currently have a $85.00 price target on the electronics maker’s stock. Rosenblatt Securities’ price objective points to a potential upside of 36.77% from the company’s previous close.

A number of other analysts also recently issued reports on DLB. Barrington Research dropped their target price on shares of Dolby Laboratories from $100.00 to $95.00 and set an “outperform” rating for the company in a research report on Wednesday, November 19th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Dolby Laboratories in a report on Monday, December 29th. Finally, Wall Street Zen upgraded Dolby Laboratories from a “hold” rating to a “buy” rating in a research note on Monday, January 5th. Three research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $92.00.

Dolby Laboratories Price Performance

Shares of DLB stock opened at $62.15 on Thursday. The firm’s 50-day simple moving average is $65.53 and its 200-day simple moving average is $69.47. Dolby Laboratories has a 1-year low of $61.33 and a 1-year high of $89.66. The firm has a market cap of $5.94 billion, a P/E ratio of 23.63 and a beta of 0.88.

Dolby Laboratories (NYSE:DLB) last issued its quarterly earnings results on Tuesday, November 18th. The electronics maker reported $0.99 EPS for the quarter, topping the consensus estimate of $0.70 by $0.29. Dolby Laboratories had a net margin of 18.90% and a return on equity of 11.99%. The firm had revenue of $307.02 million during the quarter, compared to analyst estimates of $305.76 million. During the same quarter in the prior year, the business posted $0.61 earnings per share. Dolby Laboratories’s revenue for the quarter was up .7% compared to the same quarter last year. Dolby Laboratories has set its FY 2026 guidance at 4.190-4.340 EPS and its Q1 2026 guidance at 0.790-0.940 EPS. Analysts expect that Dolby Laboratories will post 2.94 earnings per share for the current fiscal year.

Insider Activity at Dolby Laboratories

In other Dolby Laboratories news, EVP Mark Andrew Sherman sold 2,491 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $67.26, for a total transaction of $167,544.66. Following the transaction, the executive vice president directly owned 70,563 shares in the company, valued at $4,746,067.38. This represents a 3.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP John D. Couling sold 7,273 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $68.75, for a total transaction of $500,018.75. Following the completion of the sale, the senior vice president directly owned 108,065 shares of the company’s stock, valued at $7,429,468.75. The trade was a 6.31% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 137,120 shares of company stock worth $9,184,809 in the last ninety days. 37.93% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Dolby Laboratories

A number of hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada lifted its position in shares of Dolby Laboratories by 3.5% in the 1st quarter. Royal Bank of Canada now owns 68,367 shares of the electronics maker’s stock worth $5,491,000 after buying an additional 2,298 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Dolby Laboratories by 218.8% during the first quarter. Goldman Sachs Group Inc. now owns 249,574 shares of the electronics maker’s stock valued at $20,043,000 after purchasing an additional 171,288 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Dolby Laboratories by 5.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 238,216 shares of the electronics maker’s stock worth $19,131,000 after purchasing an additional 12,598 shares during the period. Focus Partners Wealth bought a new stake in shares of Dolby Laboratories in the 1st quarter worth approximately $390,000. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Dolby Laboratories by 43.0% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 17,356 shares of the electronics maker’s stock worth $1,311,000 after purchasing an additional 5,215 shares during the last quarter. Institutional investors and hedge funds own 58.56% of the company’s stock.

Dolby Laboratories Company Profile

Dolby Laboratories, Inc is a global leader in audio and imaging technologies, specializing in the development, licensing and deployment of solutions that enhance entertainment and communications experiences. The company’s core business revolves around creating advanced audio codecs, noise reduction systems and spatial sound technologies for a wide range of applications, including cinema, broadcast, gaming, streaming and personal devices. Dolby’s licensing model enables consumer electronics manufacturers, content creators and service providers to integrate its technologies into products such as televisions, smartphones, home theater systems and set-top boxes.

Among its flagship innovations are Dolby Atmos, an immersive audio format that delivers three-dimensional soundscapes for theaters and home systems; Dolby Digital and Dolby Digital Plus, widely adopted audio compression formats for broadcast and streaming; and Dolby Vision, a high-dynamic-range imaging technology that expands color, contrast and brightness in displays.